NCT04588051View on ClinicalTrials.gov

Cabozantinib in Hepatocellular Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

HCC

Interventions

DRUG

Cabozantinib

60mg daily

Trial Locations (2)

Unknown

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong

ASAN Medical Center, Seoul

All Listed Sponsors

lead

Stephen Chan Lam

OTHER